Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New type of antiobiotic tackles hard-to-treat pediatric infections

28.10.2002


Pediatricians have another weapon in their arsenal to fight infections that have shown resistance to common antibiotics, according to data presented today by a team of investigators led by Baylor College of Medicine.



Study results showed that linezolid, a new type of antibiotic, is well-tolerated and as effective as the most common antibiotic, vancomycin, in treating infants and children with known or suspected gram-positive infections, reported Dr. Sheldon Kaplan, Baylor professor of pediatrics, to the Infectious Diseases Society of America meeting in Chicago. The results were presented in four posters.

"Incidence of these infections is increasing at an alarming rate in children in the community without typical risk factors, such as recent hospitalization," said Kaplan, also chief of the infectious disease service at Texas Children’s Hospital. "This underscores the need for new treatments for children with hard-to-treat resistant gram-positive infections, because there are limited options available for this age group."


The study included children with complicated skin and soft tissue infections, nosocomial pneumonia and bacteremia caused by resistant gram- positive bacteria including methicillin-resistant staphylococcus aureus (MRSA) and methicillin-resistant staphylococcus epidermidis. The multi-center study involved 52 sites nationwide, including Baylor/Texas Children’s. It enrolled 316 children from birth to age 11, including 63 neonates. The study was an open-label, randomized comparator-controlled trial comparing linezolid to vancomycin.

According to Kaplan, antibiotic-resistant infections are now more common in the general population.

"Most of the MRSA infections we see in children now come from the community, and it is becoming increasingly difficult to manage," he said. "Oral linezolid may become one of the most important options for treating community-acquired MRSA in the future." Linezolid is marketed as ZYVOX by Pharmacia Corporation.

Lori Williams | EurekAlert!
Further information:
http://research.bcm.tmc.edu/

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

The interactome of infected neural cells reveals new therapeutic targets for Zika

23.01.2017 | Life Sciences

Melting solid below the freezing point

23.01.2017 | Materials Sciences

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

VideoLinks
B2B-VideoLinks
More VideoLinks >>>